New immunotherapy BPT567 tested in advanced cancer patients
NCT ID NCT06779851
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and find the best dose. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Hackensack Meridian John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Honor Health Research Institute
Scottsdale, Arizona, 85260, United States
-
Providence Cancer Institute
Portland, Oregon, 97213, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Start Midwest
Grand Rapids, Michigan, 49546, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.